Familial risk of cancer: Data for clinical counseling and cancer genetics
Corresponding Author
Kari Hemminki
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Fax: +49-6221-421810
Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, GermanySearch for more papers by this authorXinjun Li
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
Search for more papers by this authorKamila Czene
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
Search for more papers by this authorCorresponding Author
Kari Hemminki
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Fax: +49-6221-421810
Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, GermanySearch for more papers by this authorXinjun Li
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
Search for more papers by this authorKamila Czene
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden
Search for more papers by this authorAbstract
Familial risks for cancer are important for clinical counseling and understanding cancer etiology. Medically verified data on familial risks have not been available for all types of cancer. The nationwide Swedish Family-Cancer Database includes all Swedes born in 1932 and later (0–to 68-year-old offspring) with their parents, totaling over 10.2 million individuals. Cancer cases were retrieved from the Swedish Cancer Registry up to year 2000. Standardized incidence ratios (SIR) and 95% confidence limits (CI) were calculated for age-specific familial risk in offspring by an exact proband status. The familial risks for offspring cancer were increased at 24/25 sites from concordant cancer in only the parent, at 20/21 sites from a sibling proband and at 12/12 sites from a parent and sibling proband. The highest SIRs by parent were for Hodgkin's disease (4.88) and testicular (4.26), non-medullary thyroid (3.26), ovarian (3.15) and esophageal (3.14) cancer and for multiple myeloma (3.33). When a sibling was affected, even prostate, renal, squamous cell skin, endocrine, gastric and lung cancer and leukemia showed SIRs in excess of 3.00. The highest cumulative risks were found for familial breast (5.5%) and prostate (4.2%) cancers. We identified reliable familial risks for 24 common neoplasms, most of which lack guidelines for clinical counseling or action level. If, for example, a familial SIR of 2.2 would be use as an action level, counseling would be needed for most cancers at some diagnostic age groups. The present data provide the basis for clinical counseling. © 2003 Wiley-Liss, Inc.
REFERENCES
- 1 Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000; 26: 151–7.
- 2 Peltonen L, McKusick V. Dissecting human diseases in the postgenomic era. Science 2001; 291: 1224–9.
- 3 Peltonen L, Palotie A, Lange K. Use of population isolates for mapping of complex traits. Nat Rev Genet 2001; 1: 182–90.
- 4 Vogelstein B, Kinzler K. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill, 2002.
- 5 Houlston RS, Peto J. The future of association studies of common cancers. Hum Genet 2003; 112: 434–5.
- 6 Isaacs S, Kiemeney L, Baffo-Bonnie A, Beaty T, Walsh P. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87: 991–6.
- 7 Ponder B. Genetic testing for cancer risk. Science 1997; 278: 1050–4.
- 8 Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002; 52: 8–22.
- 9 Petersen G, Codori A-M. Genetic testing for familial cancer. In: B Vogelstein, K Kinzler, eds. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill, 2002. 643–56.
- 10 Burke W. Genetic testing. N Engl J Med 2002; 347: 1867–75.
- 11 Guttmacher AE, Collins FS. Genomic medicine—a primer. N Engl J Med 2002; 347: 1512–20.
- 12 Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 1994; 3: 209–12.
- 13 Aitken JF, Youl P, Green A, MacLennan R, Martin NG. Accuracy of case-reported family history of melanoma in Queensland, Australia. Melanoma Res 1996; 6: 313–7.
- 14 Kerber R, Slattery M. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997; 146: 244–8.
- 15 Gibbs M, Stanford J, McIndoe R, Jarvik G, Kolb S, Goode E, Chakrabari L, Schuster E, Buckley V, Miller E, Brandzel S, Li S, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999; 64: 776–87.
- 16 Glanz K, Grove J, Le Marchand L, Gotay C. Underreporting of family history of colon cancer: correlates and implications. Cancer Epidemiol Biomarkers Prev 1999; 8: 635–9.
- 17 Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H. Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 2000; 36: 1143–8.
- 18 King T, Tong L, Pack R, Spencer C, Amos C. Accuracy of family history of cancer as reported by men with prostate cancer. Urology 2002; 59: 546–50.
- 19
Carstensen B,
Soll-Johanning H,
Villadsen E,
Söndergaard J,
Lynge E.
Familial aggregation of colorectal cancer in the general population.
Int J Cancer
1996;
68:
428–35.
10.1002/(SICI)1097-0215(19961115)68:4<428::AID-IJC5>3.0.CO;2-2 CAS PubMed Web of Science® Google Scholar
- 20 Hemminki K, Jiang Y. Familial and second gastric cancers: a nation wide epidemiologic study from Sweden. Cancer 2002; 94: 1157–65.
- 21 Hemminki K, Jiang Y. Familial and second esophageal cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2002; 98: 106–9.
- 22 Hemminki K, Li X. Familial and second primary pancreatic cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2003; 103: 525–30.
- 23 Hamilton S, Aaltonen L. Tumors of the digestive system. WHO classification of tumors. Lyon: IARC, 2000. 314.
- 24 Makinen T, Tammela TL, Stenman UH, Maattanen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002: 2658–63.
- 25 Hemminki K, Li X, Plna K, Granström C, Vaittinen P. The nation-wide Swedish Family-Cancer Database: updated structure and familial rates. Acta Oncol 2001; 40: 772–7.
- 26 Hemminki K, Granström C. Risk for familial breast cancer increases with age. Nature Genet 2002; 32: 233.
- 27 Hemminki K, Li X. Familial risk of cancer by site and histopathology. Int J Cancer 2003; 103: 105–9.
- 28 Center for Epidemiology. The National Board of Health and Welfare, Stockholm. Cancer Incidence in Sweden 1998, 2000.
- 29 Esteve J, Benhamou E, Raymond L. Statistical methods in cancer research. vol. 128. Lyon: IARC, 1994.
- 30 Hemminki K, Mutanen P. Birth order, family size, and the risk of cancer in young and middle-aged adults. Br J Cancer 2001; 84: 1466–71.
- 31 Hemminki K, Vaittinen P, Dong C, Easton D. Sibling risks in cancer: clues to recessive or X-linked genes? Br J Cancer 2001; 84: 388–91.
- 32 Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600–7.
- 33 Easton D. The inherited component of cancer. Br Med Bull 1994; 50: 527–35.
- 34 Lynch H, Fusaro R, Lynch J. Hereditary cancer in adults. Cancer Detect Prev 1995; 19: 219–33.
- 35 O'Neill BP, Blondal H, Yang P, Olafsdottir GH, Sigvaldason H, Jenkins RB, Kimmel DW, Scheithauer BW, Rocca WA, Bjornsson J, Tulinius H. Risk of cancer among relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 2002; 11: 921–4.
- 36 Dong C, Hemminki K. Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer 2001; 91: 144–50.
- 37 Hemminki K, Dong C, Vaittinen P. Cancer risks to spouses and offspring in the Family-Cancer Database. Genet Epidemiol 2001; 20: 247–57.
- 38 Hemminki K, Jiang Y. Cancer risks among long-standing spouses. Br J Cancer 2002; 86: 1737–40.
- 39
Hemminki K,
Dong C,
Vaittinen P.
Familial risks in cervix cancer: is there a hereditary component?
Int J Cancer
1999;
82:
775–81.
10.1002/(SICI)1097-0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- 40 Li X, Hemminki K. Familial and second lung cancers: a nation-wide epidemiologic study from Sweden. Lung Cancer 2003; 39: 255–63.
- 41 von Knebel Doeberitz M. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002; 38: 2229–42.
- 42 Burden A, Newell J, Kavanagh G, Connor J, MacKie R. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 1999; 135: 261–5.
- 43 Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Paillerets BB, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94: 894–903.
- 44 Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003; 120: 217–23.
- 45 German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002; 97: 472–80.
- 46 Meijers-Heijboer H, van Den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55–9.
- 47 Vasen H, Mecklin J-P, Meera Khan P, Lynch H. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424–5.
- 48 Lynch H, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801–18.
- 49 Hemminki K, Li X. Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a nation-wide epidemiological study from Sweden. Br J Cancer 2001; 84: 969–74.
- 50 Hemminki K, Li X. Familial colorectal adenocarcinoma from the Swedish Family-Cancer Database. Int J Cancer 2001; 94: 743–8.
- 51 Lichtenstein P, Holm N, Verkasalo P, Illiado A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer. N Engl J Med 2000; 343: 78–85.
- 52 Hemminki K, Mutanen P. Genetic epidemiology of multistage carcinogenesis. Mutat Res 2001; 473: 11–21.
- 53 Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33–6.
- 54 Heimdal K, Olsson H, Tretli S, Flodgren P, Borresen A, Fossa S. Familial testicular cancer in Norway and southern Sweden. Br J Cancer 1996; 73: 964–9.
- 55
Westergaard T,
Olsen J,
Frisch M,
Kroman N,
Nielsen J,
Melbye M.
Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study.
Int J Cancer
1996;
66:
627–31.
10.1002/(SICI)1097-0215(19960529)66:5<627::AID-IJC8>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- 56 Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, Edwards S, Hamoudi R, Heimdal K, Fossa SD, Tucker K, Donald J, et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumors. Nat Genet 2000; 24: 197–200.
- 57 Dong C, Lonnstedt I, Hemminki K. Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 2001; 37: 1878–85.
- 58 Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM, Taylor CR, Hamilton AS, Deapen DM, Rappaport EB. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995; 332: 413–8.
- 59 Shugart Y, Hemminki K, Vaittinen P, Kingman A, Dong C. A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet 2000; 106: 553–6.
- 60 Shugart YY, Hemminki K, Vaittinen P, Kingman A. Apparent anticipation and heterogeneous transmission patterns in familial Hodgkin's and non-Hodgkin's lymphoma: report from a study based on Swedish cancer database. Leuk Lymphoma 2001; 42: 407–15.
- 61 Hemminki K, Li X. Cancer risks in twins: results from the Swedish Family-Cancer Database. Int J Cancer 2002; 99: 873–8.
- 62 Hemminki K, Czene K. Attributable risks of familial cancer from the Family-Cancer Database. Cancer Epidemiol Biomarkers Prev 2002; 11: 1638–44.
- 63 Czene K, Hemminki K. Kidney cancer from the nation-wide Swedish Family-Cancer Database: familial risks and association with second primary malignancies. Kidney Int 2002; 61: 1806–13.